Insert engineering and solubility screening improves recovery of virus-like particle subunits displaying hydrophobic epitopes

Protein Science

Volumn , Issue , 2015, Pages 1820-1828

  Abidin, R S ^a   Lua, L H L ^a   Middelberg, A P J ^a   Sainsbury, F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

aggregation; cytotoxic T cell epitope; high throughput screening; hydrophobic epitopes; hydrophobicity; protein aggregation; protein engineering; virus like particles

Indexed keywords

ASPARTIC ACID; COAT PROTEIN; EPITOPE; GLUTATHIONE TRANSFERASE;

ARTICLE; CLONE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC VARIATION; HIGH THROUGHPUT SCREENING; HYDROPHOBICITY; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; POLYOMAVIRUS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN AGGREGATION; SIZE EXCLUSION CHROMATOGRAPHY; SOLUBILITY; SPECTROPHOTOMETRY; VIRUS LIKE AGENT;

EID: 84973598715     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2775     Document Type: Article

References (45)

1. Salunke DM, Caspar DL, Garcea RL (1986) Self-assembly of purified polyomavirus capsid protein VP1. Cell 46:895–904.
2. Garcea RL, Salunke DM, Caspar DL (1987) Site-directed mutation affecting polyomavirus capsid self-assembly in vitro. Nature 329:86–87.
3. 2+-triggered switch in the thermodynamic attraction between structural protein capsomeres. J R Soc Interface 7:409–421.
4. Middelberg AP, Rivera-Hernandez T, Wibowo N, Lua LH, Fan Y, Magor G, Chang C, Chuan YP, Good MF, Batzloff MR (2011) A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 29:7154–7162.
5. Wibowo N, Chuan YP, Lua LHL, Middelberg APJ (2013) Modular engineering of a microbially-produced viral capsomere vaccine for influenza. Chem Eng Sci 103:12–20.
6. Anggraeni MR, Connors NK, Wu Y, Chuan YP, Lua LH, Middelberg AP (2013) Sensitivity of immune response quality to influenza helix 190 antigen structure displayed on a modular virus-like particle. Vaccine 31:4428–4435.
7. Chuan YP, Wibowo N, Lua LHL, Middelberg APJ (2014) The economics of virus-like particle and capsomere vaccines. Biochem Eng J 90:255.
8. Caparros-Wanderley W, Clark B, Griffin BE (2004) Effect of dose and long-term storage on the immunogenicity of murine polyomavirus VP1 virus-like particles. Vaccine 22:352–361.
9. Sapp M, Day PM (2009) Structure, attachment and entry of polyoma- and papillomaviruses. Virology 384:400–409.
10. Boura E, Liebl D, Spisek R, Fric J, Marek M, Stokrova J, Holan V, Forstova J (2005) Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells. FEBS Lett 579:6549–6558.
11. Schirmbeck R, Deml L, Melber K, Wolf H, Wagner R, Reimann J (1995) Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine 13:857–865.
12. Fric J, Marek M, Hruskova V, Holan V, Forstova J (2008) Cellular and humoral immune responses to chimeric EGFP-pseudocapsids derived from the mouse polyomavirus after their intranasal administration. Vaccine 26:3242–3251.
13. Mitic NS, Pavlovic MD, Jandrlic DR (2014) Epitope distribution in ordered and disordered protein regions—part A. T-cell epitope frequency, affinity and hydropathy. J Immunol Methods 406:83–103.
14. Cromwell ME, Hilario E, Jacobson F (2006) Protein aggregation and bioprocessing. AAPS J 8:E572–E579.
15. Chong SH, Ham S (2014) Site-directed analysis on protein hydrophobicity. J Comput Chem 35:1364–1370.
16. Chong SH, Ham S (2014) Interaction with the surrounding water plays a key role in determining the aggregation propensity of proteins. Angew Chem Int Ed Engl 53:3961–3964.
17. Chi EY, Krishnan S, Randolph TW, Carpenter JF (2003) Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20:1325–1336.
18. Wang W, Nema S, Teagarden D (2010) Protein aggregation–pathways and influencing factors. Int J Pharm 390:89–99.
19. Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM (2012) Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng Des Sel 25:591–601.
20. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A (2001) Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19:4652–4660.
21. Lipin DI, Lua LH, Middelberg AP (2008) Quaternary size distribution of soluble aggregates of glutathione-S-transferase-purified viral protein as determined by asymmetrical flow field flow fractionation and dynamic light scattering. J Chromatogr A 1190:204–214.
22. Chuan YP, Lua LH, Middelberg AP (2008) High-level expression of soluble viral structural protein in Escherichia coli. J Biotechnol 134:64–71.
23. Leibly DJ, Nguyen TN, Kao LT, Hewitt SN, Barrett LK, Van Voorhis WC (2012) Stabilizing additives added during cell lysis aid in the solubilization of recombinant proteins. PLoS One 7:e52482.
24. Tsumoto K, Umetsu M, Kumagai I, Ejima D, Philo JS, Arakawa T (2004) Role of arginine in protein refolding, solubilization, and purification. Biotechnol Prog 20:1301–1308.
25. Ho JG, Middelberg AP, Ramage P, Kocher HP (2003) The likelihood of aggregation during protein renaturation can be assessed using the second virial coefficient. Protein Sci 12:708–716.
26. Lanckriet H, Middelberg AP (2004) Operational regimes for a simplified one-step artificial chaperone refolding method. Biotechnol Prog 20:1861–1867.
27. Prashar D, Cui D, Bandyopadhyay D, Luk YY (2011) Modification of proteins with cyclodextrins prevents aggregation and surface adsorption and increases thermal stability. Langmuir 27:13091–13096.
28. Serno T, Geidobler R, Winter G (2011) Protein stabilization by cyclodextrins in the liquid and dried state. Adv Drug Deliv Rev 63:1086–1106.
29. Murphy K, Travers P, Walport M, Janeway C (2008) Janeway's immunobiology. New York: Garland Science.
30. Raghunandan R (2011) Virus-like particles: innate immune stimulators. Expert Rev Vaccines 10:409–411.
31. Josefsberg JO, Buckland B (2012) Vaccine process technology. Biotechnol Bioeng 109:1443–1460.
32. Treuheit MJ, Kosky AA, Brems DN (2002) Inverse relationship of protein concentration and aggregation. Pharm Res 19:511–516.
33. Terpe K (2003) Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 60:523–533.
34. Anggraeni MR (2014) Engineering of virus-like particles for alternative vaccine candidate targeting hypervariable peptide antigen-element. PhD Thesis, The University of Queensland. DOI:10.14264/uql.2015.135.
35. Esfandiary R, Middaugh CR, Ultraviolet absorption spectroscopy. In: Jiskoot W, Mahler H, Eds. (2012) Analysis of aggregates and particles in protein pharmaceuticals. New York: Wiley, pp 169–200.
36. Tekewe A, Connors NK, Sainsbury F, Wibowo N, Lua LH, Middelberg APJ (2015) A rapid and simple screening method to identify conditions for enhanced stability of modular vaccine candidates. Biochem Eng J 100:50–58.
37. Cohn EJ (1920) The relation between the iso-electric point of a globulin and its solubility and acid combining capacity in salt solution. Proc Natl Acad Sci USA 6:256–263.
38. Yeo TW, Lampah DA, Rooslamiati I, Gitawati R, Tjitra E, Kenangalem E, Price RN, Duffull SB, Anstey NM (2013) A randomized pilot study of l-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokinetics. PLoS One 8:e69587.
39. Polycarpou E, Zachaki S, Tsolia M, Papaevangelou V, Polycarpou N, Briana DD, Gavrili S, Kostalos C, Kafetzis D (2013) Enteral l-arginine supplementation for prevention of necrotizing enterocolitis in very low birth weight neonates: a double-blind randomized pilot study of efficacy and safety. JPEN J Parenter Enteral Nutr 37:617–622.
40. Li J, Garg M, Shah D, Rajagopalan R (2010) Solubilization of aromatic and hydrophobic moieties by arginine in aqueous solutions. J Chem Phys 133:054902.
41. Ishizuka J, Grebe K, Shenderov E, Peters B, Chen Q, Peng Y, Wang L, Dong T, Pasquetto V, Oseroff C, Sidney J, Hickman H, Cerundolo V, Sette A, Bennink JR, McMichael A, Yewdell JW (2009) Quantitating T cell cross-reactivity for unrelated peptide antigens. J Immunol 183:4337–4345.
42. Chuan YP, Fan YY, Lua L, Middelberg AP (2008) Quantitative analysis of virus-like particle size and distribution by field-flow fractionation. Biotechnol Bioeng 99:1425–1433.
43. Alexander J, Bilsel P, del Guercio MF, Marinkovic-Petrovic A, Southwood S, Stewart S, Ishioka G, Kotturi MF, Botten J, Sidney J, Newman M, Sette A (2010) Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. Human Immunol 71:468–474.
44. Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet-Noach C, Nagar S, Arnon R, Ben-Yedidia T (2009) A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 27:2099–2107.
45. Liew MWO, Rajendran A, Middelberg APJ (2010) Microbial production of virus-like particle vaccine protein at gram-per-litre levels. J Biotechnol 150:224–231.